SCHEMBL3699709

SCHEMBL3699709

c1ccc2c(-c3ccc4c(c3)OCO4)nnc(Nc3ccc(Sc4ccnc5ccncc45)cc3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
NPSR1 Q6W5P4 3/20 0.49
POLB P06746 1/20 0.49
GAA P10253 2/20 0.47
HSD17B10 Q99714 5/20 0.46
CYP1A2 P05177 5/20 0.46
CYP3A4 P08684 5/20 0.46
CYP2D6 P10635 5/20 0.46
CYP2C19 P33261 4/20 0.46
MAPK1 P28482 3/20 0.46
ALDH1A1 P00352 3/20 0.46
TP53 P04637 3/20 0.46
KDM4E B2RXH2 3/20 0.46
CYP2C9 P11712 3/20 0.46
MEN1 O00255 2/20 0.46
LMNA P02545 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALOX15 P16050 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239959 0.93 MAPT (0.51) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL15663418 0.86 MAPT (0.49) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL3697300 0.86 MAPT (0.49) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL3701300 0.85 ENPP3 (0.47) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL3699432 0.84 MAPT (0.48) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL3711392 0.84 KDR (0.51) MAPTNPSR1GAAHSD17B10CYP1A2
SCHEMBL15663504 0.83 MAPT (0.46) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL15663303 0.81 MAPT (0.44) MAPTNPSR1POLBGAAHSD17B10
SCHEMBL3702806 0.78 KDR (0.41) MAPTNPSR1POLBGAAMAPK1
SCHEMBL3711144 0.78 KDR (0.48) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2012-05-17 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 MAPT 1693/4885NPSR1 2810/4885POLB 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.